Dr. Trzepacz is a medical executive with academic medicine and pharmaceutical industry experience (Ph 2-4 Neurosciences drug development at Lilly) trained in psychosomatic medicine, geriatric psychiatry and neuropsychiatry. Clinical, teaching and research focus on cognitive and neurodegenerative disorders (Alzheimer’s, other dementias, delirium, TBI, ADHD), including diagnostic tools, drug development and biomarkers. Skills include trial design, data interpretation, publications, registration planning & submissions, product life cycle planning, and launches. Developed the Delirium Rating Scale-Revised-98, used worldwide for diagnosis and severity measurements of delirium. Professorships, NIH-funded research, and member of four journal editorial boards. As President of the American Neuropsychiatric Association and Academy of Psychosomatic Medicine, she led strategic planning and infrastructure reorganization that resulted in improved member value and fiscal standing. President & CEO of conXiome LLC for biopharma/biotech consulting. Currently Chief Medical Adviser for Elto Pharma, a subsidiary of Amarantus Bioscience Holdings Inc focused on neurodegenerative indications such as Parkinson’s disease L-DOPA-induced dyskinesia.